Malta - English - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - powder for solution for infusion or injection - cefuroxime 750 mg - antibacterials for systemic use

Malta - English - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - powder for solution for infusion or injection - cefuroxime 1500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - concentrate for solution for infusion - docetaxel 20 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - concentrate for solution for infusion - docetaxel 20 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - concentrate for solution for infusion - docetaxel 20 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; chlorphenamine maleate, quantity: 2 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; pregelatinised maize starch; povidone; purified water; erythrosine aluminium lake; stearic acid - temporary relief of the symptoms of sinus headache, pain and nasal congestion (including fever) and hay fever.

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

Ireland - English - HPRA (Health Products Regulatory Authority)

mcm pharma gmbh - zoledronic acid monohydrate - concentrate for soln for inf - 4 mg/5ml

Ireland - English - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.